Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
23 nov. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc...
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
11 nov. 2022 09h00 HE
|
Immunocore Holdings Limited
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is...
Immunocore to present at the Jefferies London Healthcare Conference
10 nov. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR),...
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
09 nov. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Net KIMMTRAK / tebentafusp revenues of £36.3 million ($40.4 million) in Q3 2022 Promising clinical activity...
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
09 sept. 2022 10h00 HE
|
Immunocore Holdings Limited
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a PRAME×CD3...
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
03 août 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc...
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
25 juin 2022 04h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor...
Immunocore Appoints Siddharth Kaul to its Board of Directors
09 juin 2022 07h45 HE
|
Immunocore Holdings Limited
Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (Nasdaq: IMCR)...
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
08 juin 2022 07h00 HE
|
Immunocore Holdings Limited
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable...
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
11 mai 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable...